All In Biotech

Drug Trial Radar · NCT06940336

To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy

A Single Arm, Multicenter, Open-label,Phase IV Clinical Study to Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients withTransthyretin Amyloid Polyneuropathy

Last checked: Nov 20, 2026Latest source record: Jul 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Jun 19, 2025

Primary completion

Jan 2028

Study completion Feb 2028

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients with Transthyretin Amyloid Polyneuropathy

Conditions

  • Transthyretin Amyloid Polyneuropathy

Interventions

  • Tafamidis Meglumine Soft CapsulesDrug

    20 mg orally once daily for 72 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline Neuropathy Impairment Score-Lower Limb (NIS-LL) at Week 72Time frame: Baseline to 72 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Qilu Hospital of Shandong University

    Jinan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.